胰性脑病临床治疗的探讨  

Clinical experience on the therapy of pancreatic encephalopathy

作　　者：钱祝银[1] 苗毅[1] 刘训良[1] 杜竞辉[1] 

机构地区：[1]南京医科大学第一附属医院普外科,江苏南京210029

出　　处：《中国现代普通外科进展》2001年第2期99-100,共2页Chinese Journal of Current Advances in General Surgery

摘　　要：目的 :探讨胰性脑病 (PE)临床治疗方法 ,降低重症急性胰腺炎 (SAP)的病死率。方法 :SAP伴发的早期可疑PE 7例 ,采用重组人生长激素 (rhGH)治疗 ,4U/次 ,每日 2次 ,5～ 7天。联合用药组以生长抑素合用rhGH治疗SAP ,共 13例 ,剂量及时间同早期PE组。结果 :应用后rhGH 2 4h ,病人精神障碍改善 ,48～ 72h后症状消失 ,本组 7例全部治愈。联合用药治疗SAP 13例 ,未见PE的发生。结论 :生长激素对早期PE有治疗作用 ,生长激素与生长抑素联合应用有可能降低PE的发生。Objective: To discuss the treatment of pancreatic encephalopathy(PE).Methods: Recombinant human growth hormone (rhGH)(Saizen)were applied in patients of severe acute pancreatitis(SAP) with suspicious early PE that presented with mental disorders. rhGH was also used in combination with somatostatin as the therapeutic method for SAP and its complication.Dosage and administration: Saizen 4U was injected intramuscularly twice a day for 5～7 days.Results: In 7 patients of this group, all of them showed improvement in the aspect of mental dysfunction and the symptoms disappeared after 48～72 hours. In 13 SAP cases underwent combined application of rhGH and somatostatin, no PE was observed.Conclusion: Application of rhGH showed therapeutic effect on the early manifestations of PE. It also suggested that combined use of rhGH and somatostatin could decrease the occurance of PE.

关 键 词：胰腺炎 胰性脑病 重组人生长激素 

分 类 号：R576[医药卫生—消化系统]